文献速递泌尿生殖技术与安全MR

全身弥散加权成像总弥散体积预测mCRPC生存

Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur Radiol · 2026-08-13

本研究为回顾性单中心研究,纳入360例骨转移为主的转移性去势抵抗性前列腺癌患者,在治疗前接受全身MRI检查。在b900 DWI上分割骨病灶并提取总弥散体积(TDV)和全局表观弥散系数(gADC),评估其对总生存期(OS)的预后意义。结果显示,TDV较高与OS显著缩短独立相关,而gADC无预后价值,TDV的多变量预后表现优于自动骨扫描指数和常规实验室指标。

要点

  • 基线全身DWI的TDV越高,mCRPC患者总生存期越短。
  • gADC与总生存期无显著关联,不宜单独用于预后分层。
  • TDV在包含或不包含aBSI数据的多变量模型中均独立预测OS。

核心结论

  • 全身弥散加权成像提取的总弥散体积(TDV)是转移性去势抵抗性前列腺癌患者总生存期的独立预测因子。
  • TDV在包含aBSI的多变量模型中预后表现优于aBSI和常规实验室指标。
  • 全局表观弥散系数(gADC)在本研究中未显示显著预后价值。

研究设计与样本

  • 回顾性单中心研究,纳入360例mCRPC且以骨转移为主的患者。
  • 所有患者在新治疗开始前接受全身MRI检查,DWI序列包含b900。
  • 骨病灶由AI辅助工具在b900 DWI上分割并经放射科医师修正。
  • 182例患者同时获得自动骨扫描指数(aBSI),85例无aBSI数据用于亚组分析。
  • 总生存期(OS)为主要终点,采用Kaplan-Meier分析和Cox回归模型评估预后关联。

关键影像表现/征象

  • 在b900 DWI图像上可见骨内高信号病灶,经分割后可量化总弥散体积(TDV)。
  • 高TDV患者中位OS为13.2个月,低于低TDV患者的33.4个月,差异显著(p<0.001)。
  • gADC反映病灶整体弥散受限程度,但组间OS差异无统计学意义。

诊断标准与关键数值

  • 高TDV与显著缩短的总生存期相关,中位OS为13.2个月对33.4个月,p<0.001。
  • 包含WBMRI和骨闪烁显像的多变量分析中,log-TDV独立预测OS,HR为1.20,p=0.027。
  • LDH>500 U/L的HR为7.79,p<0.001;ALP在200至400 U/L之间HR为1.78,p=0.019。
  • aBSI在包含log-TDV的多变量模型中无独立预后意义。
  • 无aBSI数据亚组中,log-TDV仍独立预测OS,HR为1.60,p<0.001。

临床应用与阅片要点

  • 放射科报告全身DWI时,可量化骨病灶总弥散体积作为预后分层参考。
  • TDV较高的mCRPC患者可能提示更短生存期,需在报告中提示临床关注。
  • 单独使用gADC进行预后判断缺乏依据,阅片时应结合TDV综合评估。

局限性

  • 研究为回顾性单中心设计,可能存在选择偏倚和机构依赖性。
  • 纳入患者以骨转移为主,结果未必适用于内脏转移为主的mCRPC人群。
  • aBSI仅部分患者可获得,可能影响多变量模型的统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the prognostic significance of whole-body diffusion-weighted imaging (WBDWI)-derived metrics, including total diffusion volume (TDV) and global apparent diffusion coefficient (gADC), in patients with metastatic castration-resistant prostate cancer (mCRPC).

MATERIALS AND METHODS: This retrospective single-centre study included patients with mCRPC and bone-predominant disease who underwent whole-body MRI (WBMRI) prior to the start of a new treatment. Bone lesions were segmented on b900 DWI using an AI-assisted tool with radiologist refinement, and TDV and gADC were extracted. Automated bone scan index (aBSI) was calculated when bone scintigraphy was available. Clinical and laboratory parameters were recorded. Overall survival (OS) was the primary endpoint. Kaplan-Meier analysis and Cox regression models were used to assess prognostic associations.

RESULTS: Among 360 patients, higher TDV was associated with significantly shorter OS (median OS: 13.2 vs 33.4 months; p < 0.001), whereas gADC showed no significant association. In multivariable analysis including patients with WBMRI and bone scintigraphy (n = 182), log-TDV (HR 1.20; p = 0.027), LDH > 500 U/L (HR 7.79; p < 0.001) and ALP between 200 and 400 U/L (HR 1.78; p = 0.019) were independently associated with OS, while aBSI was not. In patients without aBSI data (n = 85), log-TDV remained prognostic (HR 1.60; p < 0.001), whereas LDH and ALP were not.

CONCLUSION: TDV derived from WBDWI independently predicts OS in mCRPC and demonstrates stronger prognostic performance than aBSI and conventional laboratory markers in multivariable models, whereas gADC was not prognostic.

KEY POINTS: QuestionThere is no widely adopted quantitative imaging biomarker for prognostic stratification in mCRPC. Can whole-body diffusion-weighted MRI-derived metrics improve prognostic risk stratification in patients with bone metastases? FindingsHigher TDV of bone disease on baseline whole-body diffusion-weighted MRI was independently associated with shorter OS in patients with mCRPC. Clinical relevance Whole-body diffusion-weighted MRI-derived tumour volume may provide a practical quantitative imaging biomarker for prognostic stratification in mCRPC, potentially supporting individualised treatment planning.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. D'Erme, Avesani, Russo, et al. Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer. Eur Radiol. 2026. PMID: 42593500. doi:10.1007/s00330-026-12792-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。